Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
Holding LNTH?
Track your performance easily
LNTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$50.20 - $126.89
Previous Close$87.32
Volume2.01M
Average Volume (3M)909.05K
Market Cap
$6.07B
Enterprise Value$5.77B
Total Cash (Recent Filing)$866.39M
Total Debt (Recent Filing)$565.33M
Price to Earnings (P/E)14.5
Beta0.48
Next Earnings
Feb 20, 2025EPS Estimate
$1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.02
Shares Outstanding69,526,841
10 Day Avg. Volume1,717,421
30 Day Avg. Volume909,055
Standard Deviation0.17
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)5.85
Price to Sales (P/S)3.84
Price to Cash Flow (P/CF)16.30
P/FCF Ratio34.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.85
Enterprise Value/Gross Profit8.13
Enterprise Value/Ebitda13.12
Forecast
1Y Price Target
$131.17Price Target Upside44.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Lantheus News
PremiumCompany Announcements
Lantheus Reports Strong Q3 2024 Revenue GrowthBulls Say, Bears Say
Bulls Say
Growth PotentialThe potential for Pylarify to maintain a healthy (60%+) share of the growing PSMA PET market under favorable terms is considered valuable.
Market PositionPylarify is well-positioned to maintain category leadership based on better diagnostic sensitivity, scalability, and other supply chain benefits.
Reimbursement StabilityThe final CMS rule essentially puts to bed risk concerns around the reimbursement status of Pylarify, hence avoiding a worst-case scenario for reimbursement to fall from the current ~$5.2k level to sub ~$1k per test.
Bears Say
Clinical Trial ResultsNo material change in the radiographic progression free survival (rPFS) and overall survival (OS) of PNT2002 in the SPLASH Phase III trial after a second interim analysis.
Financial PerformanceThe company's updated annual guidance implied a softer-than-anticipated 4Q in both sales and EPS.
Reimbursement RatesPylarify will be reimbursed at a lower rate, settling roughly 40% lower versus competition for a period of 1-2 years.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $50.20 and its highest was $126.89 in the past 12 months.
What is Lantheus’s market cap?
Currently, no data Available
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Feb 20, 2025 which is in 89 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Nov 06, 2024. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.556 by $0.144.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is $1.53.
How many shares outstanding does Lantheus have?
Lantheus has 69,526,840 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.7 in its last earnings report, beating expectations of $1.556. Following the earnings report the stock price went down -20.694%.
Which hedge fund is a major shareholder of Lantheus?
Among the largest hedge funds holding Lantheus’s share is Farallon Capital Management, L.L.C.. It holds Lantheus’s shares valued at 324M.
---
Lantheus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$131.17 (44.91% Upside)
$131.17 (44.91% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 830.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.18%
12-Months-Change
Fundamentals
Return on Equity
45.53%
Trailing 12-Months
Asset Growth
34.70%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
---
LNTH Company Deck
---
LNTH Earnings Call
Q3 2024
0:00 / 0:00
---
LNTH Revenue Breakdown
65.67% PYLARIFY
21.58% DEFINITY
6.74% TechneLite
4.00% Strategic Partnerships and other revenue
2.01% Other
---
LNTH Stock 12 Month Forecast
Average Price Target
$131.17
▲(44.91% Upside)
Technical Analysis
Best Analysts Covering LNTH
1 Year
1 Year Success Rate
18/27 ratings generated profit
1 Year Average Return
+53.53%
assigned a buy rating 12 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +53.53% per trade.
---